Direct Compression Feasibility and the Particle Size Threshold in Rotary Tablet Presses

D-Glucuronolactone pharma grade API (CAS 32449-92-6) is compressed on rotary tablet presses equipped with forced feeders and precompression stations when the particle size distribution is controlled below 75 µm for the main fraction. The direct compression formulation places the API at 20–30% w/w, microcrystalline cellulose at 45–60% w/w, anhydrous dibasic calcium phosphate at 15–25% w/w, crospovidone at 2–5% w/w, and magnesium stearate at 0.5–1.0% w/w. Powder flow is mapped with USP <1174>; an angle of repose above 40° or a flow function coefficient below 4 indicates that weight variation will exceed acceptable limits on high-speed presses. Precompression force is maintained at 2–5 kN, while the main compression force for a 500 mg tablet is held between 10 kN and 18 kN to avoid edge capping and lamination when the API content exceeds 25% w/w. Punch sticking is controlled by keeping granulation loss on drying below 1.5% w/w and limiting final magnesium stearate blend time to 3 min. If the raw API lot shows loss on drying above 1.0% w/w, pre-drying in a fluid-bed dryer at 40–45°C for 2 h is applied, reducing residual water below 0.5% w/w before compression. Compressed cores are tested under USP <905> with a two-stage acceptance value of ≤15.0; friability is controlled under USP <1216> at ≤1.0% weight loss. Aqueous HPMC film coating is applied at an inlet air temperature of 60–75°C after tablet hardness reaches 40–70 N. Dissolution method transfer uses USP <711> Apparatus 2 at 50 rpm in 900 mL water; sink conditions are established before registration stability batches because the freely water-soluble lactone releases rapidly from uncoated and film-coated matrices.

What Limits Low-Dose Capsule Filling Without Roller Compaction?

When the target capsule fill weight is below 200 mg and the API content is 25–50 mg per size 3 hard capsule, direct encapsulation is constrained by cohesive flow and segregation during tamping-pin or auger filling. The dry blend is composed of API at 15–25% w/w, lactose monohydrate or mannitol as diluent, pregelatinized starch as disintegrant, colloidal silicon dioxide at 0.2–0.5% w/w, and sodium stearyl fumarate at 0.5–1.0% w/w. If USP <1174> shows an angle of repose above 35°, roller compaction or slugging is introduced before filling to increase bulk density and reduce fill weight coefficient of variation below 2.0%. On production-scale encapsulation machines, fill weight is checked with in-process weighing and final release testing under USP <905>; acceptance value ≤15.0 is required unless the dosage form qualifies for weight variation. Capsule disintegration is tested with USP <701> in water at 37±2°C; for hypromellose shells, shell rupture is assessed separately because HPMC does not dissolve rapidly in gastric fluid. The filling room is controlled at 20–25°C and 35–45% RH; gelatin shells may stick above 50% RH, while HPMC shells become brittle below 35% RH. The finished hard capsule retains the API as a crystalline powder blend without added granulation water, which minimizes lactone hydrolysis during processing.

In effervescent granule manufacture, the lactone ring of D-Glucuronolactone imposes a constraint that is absent with simple organic acid excipients. The API is combined with anhydrous citric acid, sodium bicarbonate, and sodium carbonate in low-humidity suites held below 30% RH and 18–25°C; free moisture triggers premature acid–carbonate reaction and softens the granulation. Dry granulation by roller compaction or wet granulation with 96% v/v ethanol is used instead of aqueous binder solution because the water-soluble API forms hard, non-disintegrating agglomerates when granulated with water. The granule fraction passing 1.0 mm and retained on 0.2 mm is compressed into effervescent tablets at 40–70 N hardness. Friability is controlled under USP <1216> at ≤1.0%, and disintegration is evaluated under EP 2.9.1 effervescent tablet conditions in 200 mL water at 15–25°C; complete dispersion without residue within 5 min is applied as an in-process limit. The finished strip-packed tablet or sachet includes the API as an oral powder dosage form; packaging carries a desiccant and an impermeable aluminium foil laminate because head-space humidity above 10% RH causes surface dulling and delayed disintegration.

When Terminal Sterilization Is Applied to Aqueous D-Glucuronolactone Parenterals

Injectable-grade D-Glucuronolactone is processed into small-volume parenterals as an aqueous solution at concentrations commonly between 50 mg/mL and 200 mg/mL. The principal stability conflict is hydrolytic ring opening of the lactone to D-glucuronic acid; the reaction is pH-dependent, accelerates under alkaline conditions, and receives additional thermal stress during saturated steam exposure at 121°C for 15 min. Formulation pH is adjusted with citrate or acetate buffers to a target window of 4.5–5.5, where lactone-to-acid conversion remains acceptable under terminal sterilization and short-term storage. The solution is nitrogen-sparged, filtered through a 0.22 µm PVDF or PES membrane, and filled into sterile glass ampoules or vials under Grade A conditions. Terminal sterilization is validated with a cumulative F₀ value between 8 and 12; if F₀ exceeds 12, assay loss due to hydrolysis is quantified by HPLC against a glucuronic acid reference standard. Release testing follows USP <1>, USP <788>, USP <790>, USP <71>, USP <85>, and USP <791>. Subvisible particle count for small-volume containers is controlled under USP <788> Method 1 with limits of 6000 particles per container at ≥10 µm and 600 particles per container at ≥25 µm; visible particulates are assessed under USP <790>. Bacterial endotoxin limits are calculated as K/M per USP <85>, with K taken as 5 EU/kg for parenteral administration. A move from terminal sterilization to aseptic filtration requires an ICH Q9 risk assessment and is justified only when F₀ below 8 is unavoidable.

For oral solution and syrup vehicles, the freely water-soluble D-Glucuronolactone is dissolved in purified water at 20–25°C using propeller agitation at moderate shear, then buffered to pH 4.0–5.5 with citrate–citric acid. Because the lactone ring undergoes slow hydrolytic opening in aqueous medium, prolonged high-temperature processing is avoided and the solution is filled at room temperature into amber glass or PET bottles. Preservative systems are selected against the compendial antimicrobial effectiveness test USP <51>; sodium benzoate at 0.1–0.2% w/w and potassium sorbate at 0.1–0.2% w/w are common for multi-dose oral liquids. Sweeteners and flavour aldehydes are added only after pH adjustment because residual glucuronic acid can react with aldehyde-type flavour components. The finished oral solution is tested for deliverable volume under USP <698> or the equivalent pharmacopoeial chapter; assay by HPLC is controlled at 95.0–105.0% of label claim at release. Stability is evaluated under ICH Q1A(R2) accelerated conditions at 40±2°C / 75% RH for six months; published data for this specific buffered glucuronolactone liquid configuration is limited, so real-time bracketing at 25±2°C / 60% RH remains necessary to confirm the retest period.

Roller-Compacted Granules and Segregation Control in Multi-Component Sachets

For sachet granules and dispersible tablets, D-Glucuronolactone is preblended with mannitol or sorbitol, copovidone, and an intragranular disintegrant before passing through a roller compactor. Roll pressure and roll gap are adjusted to produce ribbons that mill to granules between 0.2 mm and 1.0 mm; this narrow distribution reduces segregation of fines and over-granulated particles during transfer into sachet filling machines. Bulk density is measured with a tapped density tester, and a Carr index below 20 is targeted for reliable tamping-pin filling. The API has different density and electrostatic charge from the excipients, so a two-stage blending sequence is used: the API is blended with colloidal silicon dioxide at 0.2–0.5% w/w for 10 min, then the remaining components are added and blended for 15–20 min in a low-shear tumble mixer. The finished granule is packed into single-dose sachets or compressed into dispersible tablets meeting USP <701> disintegration in 500 mL water at 37±2°C within 3 min. Particle size distribution at release is verified by sieve analysis under USP <786> using an air-jet sieve; retained fractions are reconciled with the granule specification to prevent off-specification fill weight and non-uniform sachet delivery.